Team:HKBU/Sustainable

arrow_back

• Home
• Team
• Project
• After Project
• Human Practices
• Judging Form

• Meet the Team
• Attributions

• Description
• Engineering
• Proof of Concept
• Experimental Protocols
• Results
• Safety

• Contributions
• Implementation
• Communication
• Education and Outreach

• Collaborations
• Sustainability
• Integrated Human Practices

Sustainability

Short-term Sustainability (1-3 years)

Through our research, scientists and scholars may obtain knowledge about:

1. the important roles that sclerostin plays in regulating bone formation and in protecting the cardiovascular system;
2. The functions of sclerostin's loop 2 and loop 3 were also revealed, and inhibiting both of the loops would induce a high level of cardiovascular risk while promoting bone formation in mice with osteogenesis imperfecta (OI);
3. Loop 3 of sclerostin was critical for sclerostin’s antagonistic effect on bone formation, while the protective effect of sclerostin on cardiovascular system was independent of loop 3 of sclerostin in OI mice.

Medium-term Sustainability (4-10 years)

Our project could lead to a change in the direction of research & development direction on the subject.

From targeting sclerostin for promoting bone formation with a high safety concern on cardiovascular system in OI, to a new R&D direction, targeting sclerostin loop 3 for promoting bone formation in OI, with a low safety concern on cardiovascular system.

Long-term Sustainability (>10 years)

In the long term, we anticipate for our drug to become available in the market, and clinicians could prescribe the innovative aptamer drug for OI patients, especially for patients with cardiovascular abnormalities or with a long family history of cardiovascular diseases.

Patients suffering from OI could obtain the innovative bone anabolic drug to reverse defects in bone mass and architecture to reduce the risk of bone fractures, with trust that using the drug has a low burden on their cardiovascular system.